Group 1 - Bristol Myers Squibb is advancing lymphoma research with new data on targeted protein degradation and cell therapy presented at ASH 2025 [1] - The company aims to enhance treatment options for lymphoma patients through innovative therapeutic approaches [1] - The presentation at ASH 2025 highlights the potential of these new therapies in improving patient outcomes [1]

Bio-Techne FY Conference Summary Company Overview - **Company**: Bio-Techne (NasdaqGS: TECH) - **Date of Conference**: November 18, 2025 - **Focus**: Discussion on financial performance, market trends, and growth opportunities Key Highlights Industry Performance - **Pharma Market**: - Continued strong performance with double-digit growth for three consecutive quarters, contributing approximately 30% of total revenue [2][10] - Recent pricing mechanisms by large pharma have appeased regulatory concerns, leading to a more optimistic outlook [11] - **Spatial Biology Franchise**: - Signs of recovery with low single-digit growth in consumables and double-digit growth in instruments [3][4] - Growth in China noted for the second consecutive quarter, with expectations for continued growth [3][17] - **Biotech Market**: - Despite a 30% year-over-year decline in funding, the market showed resilience with low single-digit growth [10][14] - Recent increases in biotech funding, with October showing an 80% year-over-year growth, indicating potential recovery [15] Financial Performance - **Operating Margins**: - Expanded by 90 basis points despite challenging market conditions, attributed to portfolio management and productivity initiatives [5] - **Customer Dynamics**: - Two major cell therapy customers received FDA Fast-Track designation, which may create short-term headwinds due to reduced material purchases but is expected to enhance long-term growth potential [4][22] Market Trends - **China's Growth**: - Regulatory environment favorable for Bio-Techne, with expectations for China to become a net contributor to growth over the next 12-24 months [17][18] - Local competition exists, but brand strength and product quality remain key differentiators [20][21] - **Cell and Gene Therapy**: - Anticipated headwinds due to customer purchasing dynamics, but long-term growth prospects remain strong with potential revenue from commercialized therapies estimated at $100 million [35][36] Future Outlook - **Growth Projections**: - Confidence in achieving low single-digit organic growth in FY2026 despite near-term challenges, driven by stabilization in pharma and academic markets [58][59] - Long-term potential for double-digit growth as market conditions normalize and cell therapy commercialization ramps up [62][64] Product Development - **Innovations**: - Introduction of advanced instruments and consumables, particularly in the spatial biology and protein sciences segments, expected to drive future growth [54][50] - Ongoing development of AI-generated proteins and integration of new technologies to enhance product offerings [30][40] Additional Insights - **Market Positioning**: - Bio-Techne's focus on quality and consistency in product offerings is crucial for maintaining competitive advantage in both domestic and international markets [20][21] - **Customer Engagement**: - Continuous engagement with customers to understand their needs and preferences is vital for product development and market penetration [20] - **Long-term Strategy**: - The company is positioned to leverage its growth pillars (cell therapy, spatial, ProteinSimple) to exceed market growth rates and achieve sustainable long-term growth [63][64]

Core Insights - Bristol Myers Squibb has announced the acquisition of Orbital Therapeutics to enhance and diversify its cell therapy portfolio [1] Company Summary - The acquisition aims to strengthen Bristol Myers Squibb's position in the cell therapy market, which is a rapidly growing segment within the biopharmaceutical industry [1] - This strategic move is expected to expand the company's capabilities in developing innovative therapies for patients [1] Industry Context - The cell therapy market is witnessing significant advancements and investments, making it a key area for growth in the biopharmaceutical sector [1] - Companies are increasingly focusing on acquiring technologies and platforms that can enhance their therapeutic offerings in this competitive landscape [1]

Core Insights - The report provides a comprehensive analysis of global biologics sales, including various categories such as cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, and RNA-based drugs [1][3][5] - It highlights sales data, growth trends, and rankings of top biologics, making it essential for biopharma professionals, investors, and market analysts [1][2] Sales Data Overview - The report compiles and analyzes sales data for originator recombinant therapeutic proteins and antibodies for the year 2024, including publicly available data for biosimilars and new biologic modalities [3][5] - Sales data from 2012 to 2024 are summarized, showing growth rates and the percentage of antibody sales relative to total biologics sales [5] Product Categories - Individual product sales data are categorized into groups such as cancer antibodies, non-TNF anti-inflammatory mAbs, cardiometabolic antibodies, and more [9][10] - Target-specific sales data for cancer antibodies and non-TNF anti-inflammatory antibodies are calculated for 2024, covering various therapeutic areas [7][12] Market Trends - The report emphasizes the commercial success of novel antibody drug modalities, including antibody-drug conjugates and bispecific antibodies, with sales and growth rates presented from 2012 to 2024 [16] - A total of 75 innovator therapeutic antibodies and proteins achieved blockbuster status in 2024, each exceeding sales of US$ 1 billion [16] Company Rankings - A ranking list of the top 30 companies regarding biologics sales in 2024 is provided, along with company-specific sales data for biosimilars from 2020 to 2023 [16] - The report includes detailed sales data for various biologic products, highlighting the competitive landscape within the industry [14][16]